All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Daiichi Sankyo, AstraZeneca Withdraw EU MAA for Dato-DXd in Advanced Nonsquamous NSCLC

December 24th 2024

European approval is no longer being sought for Dato-DXd in advanced nonsquamous non–small cell lung cancer.

Rewriting the Rules for a Better Future of Cancer Care

December 24th 2024

Confidence, support, and hard work paved the way for an exceptionally successful career for Edward S. Kim, MD, MBA, who has a cemented mission in diversifying clinical trials and improving quality of life.

Combination Regimens Make Their Mark in Frontline HCC

December 24th 2024

In a Peer Exchange, HCC experts discussed how new data from the HIMALAYA, LEAP-012, EMERALD-1, and IMbrave050 trials could be used to optimize treatment.

Prophylactic Tocilizumab Reduces Toxicity, Boosts Efficacy in Immune Checkpoint Inhibitor–Treated Melanoma

December 23rd 2024

Matthew Hadfield, DO, discusses findings from a phase 2 study that used tocilizumab to reduce toxicities with immune checkpoint inhibitors in melanoma.

Osteosarcoma Spheroid Models Provide Key Tool for Preclinical Drug Development

December 23rd 2024

R. Lor Randall, MD, FACS, discusses the construction and preclinical utility of spheroid models for drug development in osteosarcoma.

The Novel Bispecific Antibody Ivonescimab May be Poised to Change the SOC in NSCLC

December 23rd 2024

Jonathan Wesley Riess, MD, MS, details the potential for ivonescimab in NSCLC after improving PFS vs pembrolizumab in the HARMONi-2 trial.

Nivolumab Plus Ipilimumab Wins European Approval for MSI-H/dMMR mCRC

December 23rd 2024

Nivolumab plus ipilimumab has been approved in Europe for the frontline treatment of adult patients with MSI-H or dMMR metastatic colorectal cancer.

Neratinib Joins NCCN Guidelines for HER2-Mutated Cervical Cancer

December 23rd 2024

The NCCN Guidelines have been updated to include neratinib for HER2-mutated recurrent/metastatic cervical cancer in the second line or later.

FDA Grants Priority Review to Taletrectinib in ROS1+ Advanced NSCLC

December 23rd 2024

The FDA has granted priority review to the NDA seeking the approval for taletrectinib in ROS1-positive advanced non–small cell lung cancer.

UC Davis Researchers Help Decode the Cause of Aggressive Breast Cancer in Women of Color

December 23rd 2024

Findings point to a biomarker that may give a “head start” to triple-negative breast cancer in Black women.

Nivolumab/CCRT Followed by Nivolumab/Ipilimumab Misses PFS End Point in Select Stage III NSCLC

December 23rd 2024

CheckMate 73L missed its primary end point of PFS in advanced unresectable stage III non–small cell lung cancer.

Tailor-Made for a Lifelong Pursuit of Precision in Cancer Care

December 23rd 2024

With a focus on closing gaps in cancer care for underserved populations, Joseph A. Sparano, MD, FACP, always strives to put patients first—a quality that has become a hallmark of his research and career in oncology.

Ongoing Research Seeks to Optimize Targeted Therapy Use in mCRC

December 22nd 2024

Aparna Parikh, MD, discussed novel agents that are currently at play in the mutated, metastatic colorectal cancer treatment field.

The OncFive: Top Oncology Articles for the Week of 12/15

December 21st 2024

The FDA awards accelerated approval to encorafenib regimen in BRAF V600E+ CRC, ensartinib wins approval in ALK+ non–small cell lung cancer, and more.

Perioperative Pembrolizumab Regimen Upholds Survival Benefit in Resectable NSCLC

December 21st 2024

The neoadjuvant/adjuvant pembrolizumab and chemotherapy combination was approved by the FDA in October 2023 for use in this patient population.

Addition of Dostarlimab to Chemo and Niraparib Maintenance Boosts PFS in Advanced Ovarian Cancer

December 20th 2024

Adding dostarlimab to chemotherapy and niraparib maintenance improved progression-free survival in first-line advanced ovarian cancer.

Venetoclax Plus PegC May Overcome Resistance to Prior BCL-2 Inhibitors in R/R AML

December 20th 2024

The addition of pegcrisantaspase to venetoclax may overcome resistance to prior BCL-2 inhibitor–based regimens for patients with relapsed/refractory AML.

FDA Grants Accelerated Approval to Encorafenib Plus Cetuximab and Chemo for BRAF V600E+ Metastatic Colorectal Cancer

December 20th 2024

The FDA has approved encorafenib plus cetuximab and mFOLFOX6 for metastatic colorectal cancer with a BRAF V600E mutation.

Filling Unmet Needs in SCAC Is Key as Incidence Rates Are Rising

December 20th 2024

Retifanlimab represents a promising agent in the squamous cell anal carcinoma field and additional research is needed to improve outcomes for patients.

China’s NMPA Approves Taletrectinib in Previously Treated ROS1+ Advanced NSCLC

December 20th 2024

China's NMPA has approved taletrectinib for locally advanced or metastatic ROS1-positive non–small cell lung cancer after a previous ROS1 TKI.